HCA Holdings price target raised to $74 from $62 at Oppenheimer Oppenheimer increased its price target on HCA after the company reported Q2 EPS that was in-line with its preannouncement but well ahead of prior Street estimates. The firm raised its estimates based on the company's guidance and keeps an Outperform rating on the shares.
HCA Holdings sees Q2 EPS about $1.18, consensus $1.32 Sees Q2 revenue $9.9B, consensus $9.77B. Q2 adjusted EBITDA is expected to be approximately $2.008B, compared to $2.0B in the previous year’s second quarter. Same facility admissions for Q2 increased 4.1%, while same facility equivalent admissions increased 4.9%. Same facility emergency room visits for Q2 increased 7.4% from the prior year’s second quarter. Same facility revenue per equivalent admission is expected to increase approximately 2.8% in Q2 compared to the prior year’s second quarter, after adjusting second quarter 2014 revenues to exclude the impact of the $142M adjustment to increase revenues related to the Texas Medicaid Waiver Program.